CRNX vs MEDP
Crinetics Pharmaceuticals, Inc. vs Medpace — AI-powered side-by-side comparison
CRNX
Crinetics Pharmaceuticals, Inc.
69
Buy
VS
| Metric | CRNX | MEDP |
|---|
| AI Score |
69
|
67
|
| Price |
$84.69
|
$578.86
|
| P/E Ratio |
-16.77×
|
33.27×
|
| ROE |
-46.9%
|
98.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.2%
|
28.8%
|
| Debt / Equity |
0.04×
|
0.28×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
46.4
|
| Beta |
0.1302
|
1.151
|
| Expected Upside |
—
|
+7.7%
|
AI Committee View
Current Innellis committee reasoning for CRNX versus MEDP.
CRNX leads by 2 points.
CRNX scores 69/100 (Buy) versus MEDP at 67/100 (Buy).
CRNX Committee View
80% agreement
5 analysts
The primary driver is 3 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 90 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 90 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
MEDP Committee View
67% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is p/e of 33.1 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 33.1 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical